However, the continuation of TNF-α inhibitor therapy, in RA patients in remission or low disease activity, increased the probability of sustained response (whether remission or low disease activity) and retarded radiographic progression in a number of published meta-analyses [7, 8]. This evidence concerns the gene TNF and rheumatoid arthritis.